-+ 0.00%
-+ 0.00%
-+ 0.00%

Implantica Q3 loss after tax narrows 23% to EUR 3.41 million; Q3 net sales more than double to EUR 748,000

PUBT·11/19/2026 07:05:11
Implantica Q3 loss after tax narrows 23% to EUR 3.41 million; Q3 net sales more than double to EUR 748,000
  • Implantica’s third-quarter 2026 loss after tax narrowed 23% to EUR 3.41 million.
  • Net sales more than doubled to EUR 748,000 from a year earlier.
  • RefluxStop secured FDA premarket approval on August 20, opening the US market for commercial launch.
  • The first US RefluxStop operations were successfully performed in early November at the University of Southern California.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Implantica AG published the original content used to generate this news brief via Cision (Ref. ID: 202611190200BITN____UKPR__SV_20261118-BIT-1321-0) on November 19, 2026, and is solely responsible for the information contained therein.